Epidemiology of Vitiligo - A Dual Population-Based Approach
- PMID: 34079380
- PMCID: PMC8165096
- DOI: 10.2147/CLEP.S304155
Epidemiology of Vitiligo - A Dual Population-Based Approach
Abstract
Background: Most epidemiological data on vitiligo refer to selected environments or focus on the prevalence of comorbidity unrelated to the population.
Objective: Aim of the study was to gain robust representative prevalence data on vitiligo and on associated dermatologic comorbidity in the German adult population.
Methods: A dual population-based approach was applied with 1) primary data obtained between 2004 and 2014 from dermatological exams in the general working population; 2) claims data from a large German statutory health insurance, reference year 2010.
Results: In the working cohort (N = 121,783; 57% male; mean age 43 years), the prevalence of vitiligo was 0.77% (0.84% in men; 0.67% in women). In the claims data (N = 1,619,678; 38% male; mean age 46 years), prevalence was 0.17% (0.14% in men; 0.18% in women). In the working cohort, vitiligo was significantly more common in people with fair skin type, ephelides and port-wine stains and less common in people with acne and solar lentigines. In the claims data, vitiligo was associated with a variety of skin conditions, eg, atopic dermatitis, psoriasis and alopecia areata.
Conclusion: The resulting discrepancy of claims vs primary data between 0.17% and 0.77% indicates the most probable spectrum of vitiligo prevalence in Germany. It is more frequently observed in clinical exams than recorded in claims data, indicating a marked proportion of people seeking no medical help. Such nonattendance may result from the fact that many treatment options do not provide satisfying benefits to the patients.
Keywords: comorbidity; health services research; pigmentation; prevalence; public health research.
© 2021 Mohr et al.
Conflict of interest statement
Prof Matthias Augustin has served as consultant and/or paid speaker for and/or has received research grants and/or honoraries for consulting and/or scientific lectures for and/or got travel expenses reimbursed and/or participated in clinical trials sponsored by companies that manufacture drugs including Abbott/AbbVie, ALK Scherax, Almirall, Amgen, Beiersdorf, Biogen Idec, BMS, Boehringer Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Forward Pharma, Fresenius, Galderma, GSK, Hexal, Incyte, Janssen-Cilag, LEO Pharma, Lilly, Medac, Menlo, Merck, MSD, Mylon, Novartis, Pfizer, Regeneron, Sandoz, Sanofi-Aventis, Stallergenes, Stiefel, Teva, TK, Trevi, UCB and Xenoport outside the submitted work. Dr Natalia Kirsten reports personal fees from AbbVie, personal fees, non-financial support from Novartis, personal fees, non-financial support from Leo, Eli Lilly, UCB, Pfizer, and Celgene, outside the submitted work. The authors declare that they have no other conflicts of interest in this work.
Figures
Similar articles
-
Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database.J Dermatol. 2025 May;52(5):841-854. doi: 10.1111/1346-8138.17643. Epub 2025 Feb 7. J Dermatol. 2025. PMID: 39921356 Free PMC article.
-
Alexithymia in different dermatologic patients.Asian J Psychiatr. 2017 Feb;25:42-45. doi: 10.1016/j.ajp.2016.10.011. Epub 2016 Oct 12. Asian J Psychiatr. 2017. PMID: 28262172
-
Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis.Adv Ther. 2024 Jul;41(7):2890-2906. doi: 10.1007/s12325-024-02875-0. Epub 2024 May 27. Adv Ther. 2024. PMID: 38802636 Free PMC article.
-
Comorbidities in vitiligo: comprehensive review.Int J Dermatol. 2018 Oct;57(10):1157-1164. doi: 10.1111/ijd.14055. Epub 2018 May 28. Int J Dermatol. 2018. PMID: 29808541 Review.
-
JAK-inhibitors in dermatology: current evidence and future applications.J Dermatolog Treat. 2019 Nov;30(7):648-658. doi: 10.1080/09546634.2018.1546043. Epub 2018 Dec 3. J Dermatolog Treat. 2019. PMID: 30433838 Review.
Cited by
-
Estimation of genetic variation in vitiligo associated genes: Population genomics perspective.BMC Genom Data. 2024 Jul 26;25(1):72. doi: 10.1186/s12863-024-01254-6. BMC Genom Data. 2024. PMID: 39060965 Free PMC article.
-
Vitiligo and the microbiome of the gut and skin: a systematic review.Arch Dermatol Res. 2025 Jan 8;317(1):201. doi: 10.1007/s00403-024-03679-6. Arch Dermatol Res. 2025. PMID: 39777551
-
Vitiligo.J Dtsch Dermatol Ges. 2025 Aug;23(8):968-987. doi: 10.1111/ddg.15706. J Dtsch Dermatol Ges. 2025. PMID: 40788636 Review.
-
[Vitiligo-update on pathogenesis, diagnostics and therapy].Dermatologie (Heidelb). 2025 Mar;76(3):168-178. doi: 10.1007/s00105-024-05467-9. Epub 2025 Feb 4. Dermatologie (Heidelb). 2025. PMID: 39904778 Review. German.
-
[Quality of life, disease burden and healthcare need of patients with vitiligo].Dermatologie (Heidelb). 2024 May;75(5):404-411. doi: 10.1007/s00105-024-05312-z. Epub 2024 Mar 11. Dermatologie (Heidelb). 2024. PMID: 38466405 Free PMC article. Review. German.
References
LinkOut - more resources
Full Text Sources